SCHEMBL7199718

SCHEMBL7199718

O=C(NO)C1(O)CNCCC1S(=O)(=O)N1CCC(OCc2cccc(F)c2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.44
PRMT6 Q96LA8 1/20 0.44
PRMT8 Q9NR22 1/20 0.44
MMP13 P45452 3/20 0.40
MMP2 P08253 1/20 0.40
MMP1 P03956 4/20 0.40
ADAM17 P78536 2/20 0.40
BCHE P06276 1/20 0.39
HDAC4 P56524 2/20 0.38
MMP14 P50281 1/20 0.38
SCN9A Q15858 1/20 0.38
PKM P14618 1/20 0.38
TSHR P16473 1/20 0.38
DRD4 P21917 2/20 0.37
P2RX7 Q99572 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KCNH2 Q12809 1/20 0.37
TACR1 P25103 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7201688 0.90 MMP13 (0.43) CARM1PRMT6MMP13MMP2MMP1
SCHEMBL7200999 0.90 MMP1 (0.46) CARM1PRMT6MMP13MMP2MMP1
SCHEMBL7200927 0.90 MMP13 (0.46) CARM1PRMT6MMP13MMP2MMP1
SCHEMBL7200956 0.89 MMP2 (0.46) CARM1PRMT6PRMT8MMP13MMP2
SCHEMBL7207975 0.88 PKM (0.42) MMP13MMP1ADAM17PKMTACR1
SCHEMBL7206549 0.85 MMP13 (0.51) CARM1PRMT6PRMT8MMP13MMP2
SCHEMBL7202653 0.85 MLNR (0.45) MMP13MMP2SLC6A2SLC6A4SLC6A3
SCHEMBL7205543 0.84 MMP13 (0.42) CARM1PRMT6MMP13MMP2MMP1
SCHEMBL7208005 0.84 MMP13 (0.42) CARM1PRMT6MMP13MMP2MMP1
SCHEMBL7201714 0.84 CHRM2 (0.43) MMP13MMP2MMP14TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 CARM1 1408/4885PRMT6 1840/4885PRMT8 3178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.